The US Food and Drug Administration “FDA” on Thursday gave full approval on a drug that delayed the progress of Alzheimer’s “modest”, while experts said this development provides a “degree of hope” to treat the disease that robs the memory. The administration previously granted the initial approval of the medicine “Lqembi” based on the ability to reduce the “amyloid” protein blocks in the brain, a step that led to Alzheimer’s disease, according to the Washington Post. The approval of “FDA” is based on Thursday based on data showing that the drug delayed the cognitive and functional decline by 27% over 18 months, compared to the imaginary means “placebo”. “Today’s procedure is the first verification that the drug has shown a clinical advantage with this devastating disease … This confirmation study has proven to be a safe and effective treatment for Alzheimer’s patients,” the list of director of the Bureau of Neurovic Science said in the “Food and Drug Administration”, Theresa Burako. The newspaper said that the drug, which is given intravenously every two weeks, is dedicated to patients in the early stages, caused by mild cognitive weakness or early dementia by Alzheimer’s disease, and a confirmed accumulation of ‘amyloid’ protein in the brain. The ‘Food and Drug Administration’ said it was asked to include the drug packaging, as a warning that it could cause the brain and the swelling of the bleeding as a possible side effect. Side effects and usually there is a side effect of any drug. The newspaper said there were three deaths related to this medicine in an extensive part of its most important experience. About 21% of participants in the experiment received by the drug suffered from swelling or bleeding in the brain, or both, compared to 9% of those who received the imaginary medicine. Elsewhere in the poster, the ‘Food and Drug Administration’ doctors request to be careful when they prescribe ‘Leqembi’ to people who use blood -blooded drugs to prevent lumps. Some clinics have said that they do not intend to give the medicine to people with blood liquidity due to the fear of brain hemorrhage. Unlike the “Washington Post”, “Leqembi”, produced by the pharmaceutical enterprise “Eisai” in Tokyo and “Biogen” in Cambridge, Massachusetts, it is not a cure and does not recover the memories destroyed by the disease, but many neurologists said it was a drug. However, the side effects of the drug, and the price of 26,500 annually, have elicited controversy over this medicine. Jerry Aforn, a professor of medicine at Harvard Medical College University, expressed concern that patients would expect the drug to work to improve their memory and thinking skills. He said, “It is not true,” and notice that it will only delay the development of the disease. He pointed out that patients who receive the drug will have to undergo various tests of the brain and perform repeated trips to injection centers, which may be a burden. Also read:
-
-
-
-
